Clinical Trials

Elderly Metastatic Colorectal Cancer Patients

NCT05745857 2026-04-13

SLURP

25 enrolled

Phase 1/2 Not yet recruiting

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT07522411 2026-04-13

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

100 enrolled

Phase NA Active not recruiting

Carcinoma, Hepatocellular

NCT04180072 2026-04-09

Atezolizumab Plus Bevacizumab With HCC and HBV Infection

51 enrolled

Carcinoma, Hepatocellular

NCT07166406 2026-04-08

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

226 enrolled

Carcinoma, Hepatocellular

NCT07466238 2026-04-08

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Phase NA Recruiting

40 enrolled

Biliary Tract Neoplasms

NCT07515625 2026-04-07

Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

46 enrolled

Stomach Neoplasms

NCT04245865 2026-04-03

Toco-CoR

83 enrolled

Colorectal Neoplasms

NCT05854498 2026-04-02

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

50 enrolled

Phase 1 Not yet recruiting

Colorectal Neoplasms

NCT07500298 2026-03-30

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

41 enrolled

Phase 1/2 Active not recruiting

Colorectal Neoplasms

NCT07491159 2026-03-24

Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study

106 enrolled

Colorectal Neoplasms

NCT07059494 2026-03-23

Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant

Phase 4 Recruiting

40 enrolled

Carcinoma, Hepatocellular

NCT07011550 2026-03-20

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

Phase 2 Suspended

7 enrolled

Microsatellite-stable Colorectal Cancer

NCT05806931 2026-03-18

SCOTI

50 enrolled

Colonic Neoplasms, Rectal Neoplasms

NCT05468359 2026-03-16

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Phase 1/2 Recruiting

64 enrolled

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT05528952 2026-03-16

TERTIO

105 enrolled

Phase EARLY_PHASE1 Active not recruiting

Carcinoma, Hepatocellular

NCT06011772 2026-03-11

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

2 enrolled

Colonic Neoplasms

NCT05665348 2026-03-09

TRIPLET

Phase 2/3 Completed

229 enrolled

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT04230187 2026-03-05

TRIBE-C

528 enrolled

Colorectal Neoplasms

NCT04563338 2026-03-05

An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)

36 enrolled

Carcinoma, Hepatocellular

NCT04721132 2026-03-05

Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

16 enrolled

Phase 3 Active not recruiting

Carcinoma, Hepatocellular

NCT04094688 2026-03-03

SOLARIS

455 enrolled 13 charts

Colorectal Adenocarcinoma

NCT04215731 2026-03-03

FOBEAR

582 enrolled

Phase EARLY_PHASE1 Recruiting

Rectal Neoplasms

NCT07193862 2026-02-27

Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis

10 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Colorectal Cancer Metastatic

NCT07318389 2026-02-27

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

100 enrolled

Colorectal Neoplasms

NCT03942328 2026-02-24

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Phase 1/2 Recruiting

85 enrolled

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT05488522 2026-02-20

SBRT With Atezo/Bev for HCC

Phase 1 Recruiting

18 enrolled

Phase 3 Active not recruiting

Carcinoma, Hepatocellular

NCT05171660 2026-02-17

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

446 enrolled

Colorectal Neoplasms

NCT07407465 2026-02-17

CHIMERA

42 enrolled

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT04109924 2026-02-10

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

Phase 2 Completed

42 enrolled 12 charts

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05546879 2026-02-10

Liver-NET1

Phase 1 Suspended

43 enrolled

Carcinoma, Hepatocellular

NCT07395063 2026-02-09

A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.

68 enrolled

Colorectal Neoplasms

NCT04587128 2026-02-05

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

34 enrolled

Colorectal Neoplasms

NCT06268015 2026-02-05

BBOpCo

16 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT07389265 2026-02-05

CAPRI-3 GOIM

480 enrolled

Colorectal Neoplasms

NCT07383285 2026-02-03

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

106 enrolled

Rectal Neoplasms Malignant

NCT07381764 2026-02-02

ROMANCE - GOIM

150 enrolled

Colorectal Neoplasms

NCT07359456 2026-01-22

COLIBRI-GI

130 enrolled

Colorectal Neoplasms

NCT07005570 2026-01-21

Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）

86 enrolled

pMMR/MSS Locally Advanced Rectal Cancer

NCT00826540 2026-01-20

Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Phase 2 Completed

83 enrolled 10 charts

Colonic Neoplasms, Rectal Neoplasms

NCT07347951 2026-01-16

A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer

30 enrolled

Phase 4 Not yet recruiting

Rectal Neoplasms

NCT07094893 2026-01-14

ARIEL-ENGIC

280 enrolled

Colorectal Neoplasms

NCT07337551 2026-01-13

Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive

20 enrolled

Colorectal Neoplasms

NCT04689347 2026-01-12

5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

Phase 1/2 Recruiting

27 enrolled

Phase 1/2 Active not recruiting

Colorectal Neoplasms

NCT04564898 2026-01-08

TriComB

48 enrolled

Phase 1 Active not recruiting

Colorectal Cancer Metastatic

NCT06838338 2026-01-08

JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC

30 enrolled

Colorectal Neoplasms

NCT07229846 2026-01-08

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

30 enrolled

Colorectal Neoplasms

NCT06332079 2026-01-05

HAITI

Phase 2 Terminated

4 enrolled

Colorectal Cancer Metastatic

NCT07317414 2026-01-05

β-alanine in the Treatment of Advanced Hepatocellular Carcinoma

158 enrolled